Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: Awaiting the results of ongoing clinical trials

Massimo Di Maio, Gennaro Daniele, Maria Carmela Piccirillo, Pasqualina Giordano, Giuseppe Signoriello, Bruno Daniele, Francesco Perrone

Research output: Contribution to journalArticle

Abstract

No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. Currently, sorafenib represents standard treatment for patients with advanced HCC and well-preserved liver function, whilst the evidence about its effectiveness in patients with more severe liver impairment is less robust. A randomized trial to demonstrate the efficacy of sorafenib in Child-Pugh B patients with advanced HCC is currently ongoing. In the meantime, several trials are testing the role of sorafenib in early HCC (as adjuvant treatment after potentially curative loco-regional therapies) and in intermediate stage (exploring different modalities of integration of sorafenib with trans-arterial chemo-embolization). The results of all these trials will better define the potentiality and the boundaries of use of sorafenib in HCC patients.

Original languageEnglish
Pages (from-to)549-565
Number of pages17
JournalCancers
Volume4
Issue number2
DOIs
Publication statusPublished - Jun 2012

Keywords

  • Child-Pugh B patients
  • Hepatocellular carcinoma
  • Sorafenib
  • Trans-arterial chemo-embolization

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: Awaiting the results of ongoing clinical trials'. Together they form a unique fingerprint.

  • Cite this